Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week Low – Time to Sell?

Royalty Pharma plc (NASDAQ:RPRX) shares reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $25.12 and last traded at $25.64, with a volume of 394313 shares trading hands. The stock had previously closed at $25.58.

Analysts Set New Price Targets

Several analysts recently commented on the stock. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. The Goldman Sachs Group raised their target price on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, Citigroup cut their price target on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Royalty Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $41.67.

Royalty Pharma Price Performance

The stock has a 50 day moving average price of $27.53 and a 200-day moving average price of $27.48. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The stock has a market capitalization of $15.32 billion, a price-to-earnings ratio of 13.25, a price-to-earnings-growth ratio of 3.78 and a beta of 0.47.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.25%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma’s payout ratio is 43.52%.

Institutional Investors Weigh In On Royalty Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Swedbank AB raised its holdings in shares of Royalty Pharma by 2.0% during the 3rd quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company’s stock worth $311,964,000 after acquiring an additional 213,900 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Royalty Pharma by 58.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock worth $84,915,000 after purchasing an additional 1,103,341 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Royalty Pharma by 6.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,972,201 shares of the biopharmaceutical company’s stock valued at $84,084,000 after purchasing an additional 174,874 shares during the last quarter. New South Capital Management Inc. grew its stake in shares of Royalty Pharma by 5.0% in the 3rd quarter. New South Capital Management Inc. now owns 2,466,371 shares of the biopharmaceutical company’s stock valued at $69,774,000 after buying an additional 117,394 shares during the period. Finally, Homestead Advisers Corp increased its holdings in shares of Royalty Pharma by 40.7% during the 1st quarter. Homestead Advisers Corp now owns 1,892,540 shares of the biopharmaceutical company’s stock worth $57,502,000 after buying an additional 547,000 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.